Finance·1 min read·Author: Koreabw AI Desk

Korea Investment & Securities Raises Celltrion Target Price by 8%

Korea Investment & Securities has increased its target price for Celltrion due to strong new product sales.

Updated: Nov 17, 2026, 01:22 PM GMT-3
Sharefin
Koreabw AI

Korea Investment & Securities has increased its target price for Celltrion due to strong new product sales.

Korea Investment & Securities announced on November 17 that it has raised its target price for Celltrion by 8%, bringing it to 280,000 won. This adjustment is based on expectations of improved profitability driven by the successful sales of five new products.

Analyst Wi Hae-ju stated that the gross margin is projected to improve to 62.3% as these new products gain traction in the market. The firm maintains a buy rating on Celltrion, which closed at 214,500 won in the previous trading session.

The forecast for Celltrion's revenue next year stands at 6.5888 trillion won, reflecting a 15% increase from the current year, while operating profit is expected to rise by 21% to 2.2948 trillion won. This growth is primarily attributed to the new product line, including the notable OMLYCLO biosimilar, which has seen a surge in demand after its U.S. launch.

Looking ahead, Korea Investment & Securities anticipates a compound annual growth rate (CAGR) of 22% for revenue and 33% for operating profit from 2025 to 2028. The firm highlighted that the new products are expected to drive significant profit growth, with a projected revenue CAGR of 97% for the same period.

With ongoing research and development efforts, including upcoming trials for new drug candidates, Celltrion is well-positioned for future growth. The analyst noted that the market is likely to respond positively to the anticipated launches, particularly as the company prepares for products expected to hit the market in 2028.

Related companies

Where it matters

KR
TagsCelltrionKorea Investment & Securitiestarget pricenew productsprofitability

Related coverage